Moderna soars after STAT reports “a buyout or a large partnership” are on the table
Moderna rose nearly 15% on Thursday after STAT reported that the company has flirted with the idea of tying up with a larger drugmaker.
The Covid vaccine maker has talked to at least one large drugmaker on a deal “of significant scope” that could be either “a buyout or a large partnership,” a source told STAT.
The company is perhaps best known for being tapped by the US government to quickly develop a vaccine for COVID-19 in 2020, which remains its single source of revenue. But the company has yet to add new products to its portfolio and is faced with a second Trump administration hostile to its sole product, and investors are growing impatient.
The company is perhaps best known for being tapped by the US government to quickly develop a vaccine for COVID-19 in 2020, which remains its single source of revenue. But the company has yet to add new products to its portfolio and is faced with a second Trump administration hostile to its sole product, and investors are growing impatient.
.jpg)
